Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-24-007903
Filing Date
2024-11-12
Accepted
2024-11-12 16:30:29
Documents
46
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR SEPT 2024 xenetic_i10q-093024.htm   iXBRL 10-Q 514596
2 CERTIFICATION xenetic_ex3101.htm EX-31.1 10156
3 CERTIFICATION xenetic_ex3102.htm EX-31.2 10173
4 CERTIFICATION xenetic_ex3201.htm EX-32.1 4277
  Complete submission text file 0001683168-24-007903.txt   2616917

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE xbio-20240930.xsd EX-101.SCH 18591
6 XBRL CALCULATION FILE xbio-20240930_cal.xml EX-101.CAL 24674
7 XBRL DEFINITION FILE xbio-20240930_def.xml EX-101.DEF 84174
8 XBRL LABEL FILE xbio-20240930_lab.xml EX-101.LAB 201829
9 XBRL PRESENTATION FILE xbio-20240930_pre.xml EX-101.PRE 163449
48 EXTRACTED XBRL INSTANCE DOCUMENT xenetic_i10q-093024_htm.xml XML 266895
Mailing Address 945 CONCORD ST. FRAMINGHAM MA 01701
Business Address 945 CONCORD ST. FRAMINGHAM MA 01701 781-778-7720
Xenetic Biosciences, Inc. (Filer) CIK: 0001534525 (see all company filings)

EIN.: 452952962 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37937 | Film No.: 241448888
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)